ORTX - bluebird bio trial suspension hurts Orchard and AVROBIO

Before the open, bluebird bio ([[BLUE]] -33.6%) announced it was suspending two Phase 1/2 clinical trials for the gene therapy candidate, LentiGlobin in sickle cell disease (“SCD”)The investigations were ongoing to determine if there was a relationship to the use of BB305 lentiviral vector in the manufacture of LentiGlobin for SCD, the company added.The losses have extended to several other developers involving lentiviral vectors in their portfolios, namely AVROBIO ([[AVRO]] -17.5%), Orchard Therapeutics ([[ORTX]] -14.6%) and Rocket Pharmaceuticals ([[RCKT]] -7.6%).Here is a look back at some of the latest updates on their programs involving lentiviral vectors.In 2H 2021, AVROBIO expects to commence a Phase 1/2 trial for investigational lentiviral gene therapy (AVR-RD-05) for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.In November, Orchard Therapeutics received FDA signoff for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy targeting metachromatic leukodystrophy.Thanks to its ongoing lentiviral gene therapy programs (noted in the diagram as LVV),

For further details see:

bluebird bio trial suspension hurts Orchard and AVROBIO